To use all functions of this page, please activate cookies in your browser.
My watch list
my.bionity.com
my.bionity.com
With an accout for my.bionity.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
- My watch list
- My saved searches
- My saved topics
- My newsletter
42 Current news of Actelion
rss
Actelion's macitentan meets primary endpoint in pivotal Phase III study
05-03-2012
Actelion announced that initial analysis indicates that the pivotal, long-term, event-driven study SERAPHIN with macitentan, a novel dual endothelin receptor antagonist, in 742 patients suffering from pulmonary arterial hypertension (PAH) and treated for up to three and a half years, has met ...
Japan's Ministry of Health, Labour and Welfare grants approval for Actelion's miglustat for the treatment of Niemann-Pick type C disease
04-04-2012
Actelion Ltd announced that Japan's Ministry of Health, Labour and Welfare has granted approval for miglustat for the treatment of Niemann-Pick type C disease.The approval was based on the data generated for the first approval of miglustat in this indication in the European Union, as well as ...
Auxilium Pharmaceuticals, Inc. and Actelion Pharmaceuticals Ltd. enter a collaboration agreement for XIAFLEX in Canada, Australia, Brazil and Mexico
Actelion obtains exclusive rights for two potential indications
02-24-2012
Auxilium Pharmaceuticals, Inc. and Actelion Ltd. announced that they have entered into a long-term partnership for the development, supply and commercialization of XIAFLEX® (collagenase clostridium histolyticum), a novel, first-in-class biologic for the potential treatment of Dupuytren's ...
Jean-Pierre Garnier elected as Chairman of Actelion's Board of Directors
09-30-2011
Actelion Ltd announced that Jean-Pierre Garnier has become Chairman of the Board of Directors of the Swiss biopharmaceutical company. The Board of Directors elected him at their meeting, 27 September 2011. In order to ensure a smooth transition, Robert Cawthorn, who has been Chairman since ...
Actelion reports results of exploratory study with macitentan in IPF patients
08-30-2011
Actelion announced that the exploratory Phase II study with macitentan in patients with idiopathic pulmonary fibrosis (IPF) shows a promising safety and tolerability profile of macitentan, no difference being observed between placebo and macitentan with regard to liver enzyme elevations. The ...
Actelion announces change in its Board of Directors
08-04-2011
Actelion announced that Joseph C. Scodari - for personal reasons - has resigned from Actelion's Board of Directors at the beginning of August 2011.Robert Cawthorn, Chairman of the Board of Directors at Actelion, commented: "We would like to thank Joe for his dedication to Actelion. We have ...
Actelion's selective S1P1 receptor agonist ponesimod successful in mid-stage trial for multiple sclerosis
Ponesimod to proceed to Phase III final stage of clinical development
08-03-2011
Actelion announced that the primary endpoint - reduction in the number of new active inflammatory lesions in the brain - has been met with its selective S1P1 receptor agonist, ponesimod, in a Phase IIb dose-finding study in patients with relapsing-remitting multiple sclerosis.The study ...
Actelion announces change in its management structure
Otto Schwarz appointed Chief Operating Officer
06-09-2011
Actelion Ltd announced that Otto Schwarz has been appointed Chief Operating Officer (COO). Otto Schwarz joined Actelion in 2008 as Head of Business Strategy & Operations. In addition to Commercial Operations and Business Strategy he assumes responsibility for Corporate Services, Global ...
Actelion's novel CRTH2 antagonist meets primary endpoint in Phase II study in patients with seasonal allergic rhinitis
05-25-2011
Actelion Ltd announced that a Phase II study with its novel orally-active CRTH2 antagonist in seasonal allergic rhinitis has met its primary endpoint with statistical significance (pThe study assessed the efficacy and tolerability of various doses of this novel CRTH2 antagonist in adult ...
Jean-Pierre Garnier and Robert Bertolini nominated to join Actelion's Board
04-06-2011
Actelion Ltd announced the nomination of Jean-Pierre Garnier and Robert Bertolini for election to the Company's Board of Directors at the 2011 Annual General Meeting (AGM) of shareholders, to be held on 05 May 2011. When elected, Jean-Pierre Garnier will become a Vice Chairman together with ...
